SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay.
RT-LAMP
SARS-CoV-2
clinical diagnostic
Journal
Wellcome open research
ISSN: 2398-502X
Titre abrégé: Wellcome Open Res
Pays: England
ID NLM: 101696457
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
10
05
2021
entrez:
8
6
2021
pubmed:
9
6
2021
medline:
9
6
2021
Statut:
epublish
Résumé
The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical research institute, in collaboration between partner hospitals and an accredited clinical diagnostic laboratory, established a diagnostic testing pipeline that has reported on more than 252,000 RT-qPCR results since its commencement at the beginning of April 2020. However, due to ongoing demand and competition for critical resources, alternative testing strategies were sought. In this work, we present a clinically-validated procedure for high-throughput SARS-CoV-2 detection by RT-LAMP that is robust, reliable, repeatable, specific, and inexpensive.
Identifiants
pubmed: 34095506
doi: 10.12688/wellcomeopenres.16517.2
pmc: PMC8170534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Subventions
Organisme : Wellcome Trust
ID : FC001136
Pays : United Kingdom
Informations de copyright
Copyright: © 2021 Buck MD et al.
Déclaration de conflit d'intérêts
Competing interests: D. Miller and K. Gulati are employees of New England Biolabs, which provided the WarmStart Colorimetric LAMP 2X Master Mix used in this work. C. Swanton receives or has received grant support from Pfizer, AstraZeneca, Bristol-Myers Squibb (BMS), Roche-Ventana, Boehringer-Ingelheim, and Ono Pharmaceutical and has consulted for or received an honorarium from Pfizer, Novartis, GlaxoSmithKline, Merck Sharp & Dohme, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Venatana, GRAIL, Medicxi, and the Sarah Cannon Research Institute. C. Swanton also is a shareholder of Apogen Biotechnologies, Epic Bioscience, and GRAIL and has stock options in and is a cofounder of Achilles Therapeutics.
Références
Rev Med Virol. 2020 May;30(3):e2106
pubmed: 32302058
Clin Chem. 2021 Jan 30;67(2):415-424
pubmed: 33098427
J Infect. 2021 Jan;82(1):117-125
pubmed: 33271166
BMC Infect Dis. 2019 Aug 1;19(1):676
pubmed: 31370782
J Infect Dis. 2020 Oct 1;222(9):1462-1467
pubmed: 32798217
Cell Rep Methods. 2021 May 24;1(1):100005
pubmed: 34235497
Anal Chem. 2020 Dec 15;92(24):16204-16212
pubmed: 33238709
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24450-24458
pubmed: 32900935
Sci Rep. 2018 Feb 28;8(1):3803
pubmed: 29491389
J Infect Chemother. 2009 Apr;15(2):62-9
pubmed: 19396514
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nucleic Acids Res. 2000 Jun 15;28(12):E63
pubmed: 10871386
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32719001
Sens Actuators Rep. 2020 Nov;2(1):100017
pubmed: 35047828
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
PLoS Negl Trop Dis. 2020 Nov 4;14(11):e0008855
pubmed: 33147214
Lancet Microbe. 2021 Jul;2(7):e311-e319
pubmed: 33846704
J Infect Chemother. 2021 Feb;27(2):410-412
pubmed: 33214073
Biotechniques. 2020 Sep;69(3):178-185
pubmed: 32635743
Wellcome Open Res. 2021 Jan 21;6:9
pubmed: 34095506